Literature DB >> 7298870

Biological activity of cannabichromene, its homologs and isomers.

C E Turner, M A Elsohly.   

Abstract

Cannabichromene (CBC) is one of four major cannabinoids in Cannabis sativa L. and is the second most abundant cannabinoid in drug-type cannabis. Cannabichromene and some of its homologs, analogs, and isomers were evaluated for antiinflammatory, antibacterial, and antifungal activity. Antiinflammatory activity was evaluated by the carrageenan-induced rat paw edema and the erythrocyte membrane stabilization method. In both tests, CBC was superior to phenylbutazone. Antibacterial activity of CBC and its isomers and homologs was evaluated using gram-positive, gram-negative, and acid-fast bacteria. Antifungal activity was evaluated using yeast-like and filamentous fungi and a dermatophyte. Antibacterial activity was strong, and the antifungal activity was mild to moderate.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7298870     DOI: 10.1002/j.1552-4604.1981.tb02606.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  15 in total

1.  Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice.

Authors:  Angelo A Izzo; Raffaele Capasso; Gabriella Aviello; Francesca Borrelli; Barbara Romano; Fabiana Piscitelli; Laura Gallo; Francesco Capasso; Pierangelo Orlando; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

2.  Cannabichromene is a cannabinoid CB2 receptor agonist.

Authors:  Michael Udoh; Marina Santiago; Steven Devenish; Iain S McGregor; Mark Connor
Journal:  Br J Pharmacol       Date:  2019-11-21       Impact factor: 8.739

3.  Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.

Authors:  Luciano De Petrocellis; Alessia Ligresti; Aniello Schiano Moriello; Marco Allarà; Tiziana Bisogno; Stefania Petrosino; Colin G Stott; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

4.  Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol.

Authors:  Gerald T DeLong; Carl E Wolf; Alphonse Poklis; Aron H Lichtman
Journal:  Drug Alcohol Depend       Date:  2010-11-01       Impact factor: 4.492

5.  The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis.

Authors:  B Romano; F Borrelli; I Fasolino; R Capasso; F Piscitelli; Mg Cascio; Rg Pertwee; D Coppola; L Vassallo; P Orlando; V Di Marzo; Aa Izzo
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

6.  Anti-Bacterial Properties of Cannabigerol Toward Streptococcus mutans.

Authors:  Muna Aqawi; Ronit Vogt Sionov; Ruth Gallily; Michael Friedman; Doron Steinberg
Journal:  Front Microbiol       Date:  2021-04-22       Impact factor: 5.640

Review 7.  Cannabis sativa: Interdisciplinary Strategies and Avenues for Medical and Commercial Progression Outside of CBD and THC.

Authors:  Jackson M J Oultram; Joseph L Pegler; Timothy A Bowser; Luke J Ney; Andrew L Eamens; Christopher P L Grof
Journal:  Biomedicines       Date:  2021-02-26

Review 8.  The antimicrobial effect behind Cannabis sativa.

Authors:  Laureano Schofs; Mónica D Sparo; Sergio F Sánchez Bruni
Journal:  Pharmacol Res Perspect       Date:  2021-04

9.  Pharmacokinetics of cannabichromene in a medical cannabis product also containing cannabidiol and Δ9-tetrahydrocannabinol: a pilot study.

Authors:  Erica N Peters; Laura MacNair; Irina Mosesova; Uwe Christians; Cristina Sempio; Jost Klawitter; M Hunter Land; Mark A Ware; Cynthia Turcotte; Marcel O Bonn-Miller
Journal:  Eur J Clin Pharmacol       Date:  2021-10-18       Impact factor: 2.953

Review 10.  Role of Cannabinoids in Gastrointestinal Mucosal Defense and Inflammation.

Authors:  Klára Gyires; Zoltán S Zádori
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.